Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled data from up to three years of treatment in randomized phase 3 trials.

Kenneth B GordonRichard G LangleyRichard Bruce WarrenYukari OkuboDavid RosmarinMark LebwohlLuke PetersonCynthia MaddenDirk de CuyperOwen DaviesDiamant Thaҫi

Published in: The British journal of dermatology (2023)

NCT03412747, NCT03370133, NCT03410992, NCT03598790.

Keyphrases

phase iii
double blind
open label
coronary artery disease
electronic health record
early onset
placebo controlled
clinical trial
high intensity
big data
combination therapy